Effects of fasudil on pulmonary hypertension in clinical practice

• Published in: Pulmonary pharmacology & therapeutics Vol. 46; pp. 54 - 63
• Main Authors: Zhang, Yiqing, Wu, Shangjie
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.10.2017
• Subjects: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - administration & dosage; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - adverse effects; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - analogs & derivatives; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - pharmacology; Animals; Disease Models, Animal; Drug Synergism; Fasudil; Humans; Hypertension, Pulmonary - drug therapy; Hypertension, Pulmonary - physiopathology; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - pharmacology; Pulmonary arterial hypertension; Pulmonary hypertension; rho-Associated Kinases - antagonists & inhibitors; Rho-kinase; PVR/SVR; ROCK; SAP; RHC; PVR; SVR; SaO2; TPR; Pulmonary arterial hypertension; PASMC; SvO2; CI; Rho-kinase; CO; IPAH; Pulmonary hypertension; Fasudil; ET; CTD; ERA; PAH; PH; CTEPH; Qp/Qs; PDEI; 6MWD; CHD; PAP; MCT

Pulmonary hypertension (PH) is a pathophysiologic disorder that may involve multiple clinical conditions and can complicate the majority of cardiovascular and respiratory diseases. The presence of PH is associated with worse outcomes, but the efficacy of current therapy is still unsatisfactory. Beca...